MedTrace Logo

ARB, ACEi, DRi Effects on COVID-19 Course Disease

NCT04364984 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2023-03-21

Study results available
· View outcomes & findings →

Summary

It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.

Conditions

Interventions

DRUG

Angiotensin converting enzyme inhibitor

routine drug intake

DRUG

Angiotensin Receptor Blockers

routine drug intake

DRUG

Direct renin inhibitor

routine drug intake

Sponsors & Collaborators

  • Medical Practice Prof D. Ivanov

    lead OTHER

Principal Investigators

  • Iryna Zavalna, MD · Nephrology clinic

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2021-07-24
Completion
2021-08-01
FDA Drug
Yes

Countries

  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04364984 on ClinicalTrials.gov